Understanding the Interaction of Hepatitis C Virus with Host DEAD-box RNA Helicases

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2014 Mar 25

PMID 24659882

Citations 17

Authors

Megha Haridas Upadya

Jude Juventus Aweya

Yee-Joo Tan

Affiliations

Soon will be listed here.

Abstract

The current therapeutic regimen to combat chronic hepatitis C is not optimal due to substantial side effects and the failure of a significant proportion of patients to achieve a sustained virological response. Recently developed direct-acting antivirals targeting hepatitis C virus (HCV) enzymes reportedly increase the virologic response to therapy but may lead to a selection of drug-resistant variants. Besides direct-acting antivirals, another promising class of HCV drugs in development include host targeting agents that are responsible for interfering with the host factors crucial for the viral life cycle. A family of host proteins known as DEAD-box RNA helicases, characterized by nine conserved motifs, is known to play an important role in RNA metabolism. Several members of this family such as DDX3, DDX5 and DDX6 have been shown to play a role in HCV replication and this review will summarize our current knowledge on their interaction with HCV. As chronic hepatitis C is one of the leading causes of hepatocellular carcinoma, the involvement of DEAD-box RNA helicases in the development of HCC will also be highlighted. Continuing research on the interaction of host DEAD-box proteins with HCV and the contribution to viral replication and pathogenesis could be the panacea for the development of novel therapeutics against HCV.

Citing Articles

PRRSV hijacks DDX3X protein and induces ferroptosis to facilitate viral replication.

Mao Q, Ma S, Li S, Zhang Y, Li S, Wang W Vet Res. 2024; 55(1):103.

PMID: 39155369 PMC: 11331664. DOI: 10.1186/s13567-024-01358-y.

Serine-arginine protein kinases and their targets in viral infection and their inhibition.

Zheng K, Ren Z, Wang Y Cell Mol Life Sci. 2023; 80(6):153.

PMID: 37198350 PMC: 10191411. DOI: 10.1007/s00018-023-04808-6.

DDX5: an expectable treater for viral infection- a literature review.

Hu M, Zheng H, Wu J, Sun Y, Wang T, Chen S Ann Transl Med. 2022; 10(12):712.

PMID: 35845539 PMC: 9279824. DOI: 10.21037/atm-22-2375.

STING nuclear partners contribute to innate immune signaling responses.

Dixon C, Malik P, de Las Heras J, Saiz-Ros N, de Lima Alves F, Tingey M iScience. 2021; 24(9):103055.

PMID: 34541469 PMC: 8436130. DOI: 10.1016/j.isci.2021.103055.

An E2F1/DDX11/EZH2 Positive Feedback Loop Promotes Cell Proliferation in Hepatocellular Carcinoma.

Su S, Li Q, Zhang M, Zhang P, Shen H, Zhang C Front Oncol. 2021; 10:593293.

PMID: 33614480 PMC: 7892623. DOI: 10.3389/fonc.2020.593293.

References

Huang Z, Murray M, Secrist 3rd J . Recent development of therapeutics for chronic HCV infection. Antiviral Res. 2006; 71(2-3):351-62. DOI: 10.1016/j.antiviral.2006.06.001. View

Poordad F, McCone Jr J, Bacon B, Bruno S, Manns M, Sulkowski M . Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364(13):1195-206. PMC: 3766849. DOI: 10.1056/NEJMoa1010494. View

MacDonald A, Harris M . Hepatitis C virus NS5A: tales of a promiscuous protein. J Gen Virol. 2004; 85(Pt 9):2485-2502. DOI: 10.1099/vir.0.80204-0. View

Sekine S, Ogawa R, Ito R, Hiraoka N, McManus M, Kanai Y . Disruption of Dicer1 induces dysregulated fetal gene expression and promotes hepatocarcinogenesis. Gastroenterology. 2009; 136(7):2304-2315.e1-4. PMC: 3167383. DOI: 10.1053/j.gastro.2009.02.067. View

Caruthers J, Johnson E, McKay D . Crystal structure of yeast initiation factor 4A, a DEAD-box RNA helicase. Proc Natl Acad Sci U S A. 2000; 97(24):13080-5. PMC: 27181. DOI: 10.1073/pnas.97.24.13080. View

Schroder M . Human DEAD-box protein 3 has multiple functions in gene regulation and cell cycle control and is a prime target for viral manipulation. Biochem Pharmacol. 2009; 79(3):297-306. DOI: 10.1016/j.bcp.2009.08.032. View

Chatel-Chaix L, Germain M, Gotte M, Lamarre D . Direct-acting and host-targeting HCV inhibitors: current and future directions. Curr Opin Virol. 2012; 2(5):588-98. DOI: 10.1016/j.coviro.2012.08.002. View

Deng L, Adachi T, Kitayama K, Bungyoku Y, Kitazawa S, Ishido S . Hepatitis C virus infection induces apoptosis through a Bax-triggered, mitochondrion-mediated, caspase 3-dependent pathway. J Virol. 2008; 82(21):10375-85. PMC: 2573220. DOI: 10.1128/JVI.00395-08. View

Mohd-Ismail N, Deng L, Sukumaran S, Yu V, Hotta H, Tan Y . The hepatitis C virus core protein contains a BH3 domain that regulates apoptosis through specific interaction with human Mcl-1. J Virol. 2009; 83(19):9993-10006. PMC: 2748021. DOI: 10.1128/JVI.00509-09. View

10.

von Hahn T, Ciesek S, Manns M . Arrest all accessories--inhibition of hepatitis C virus by compounds that target host factors. Discov Med. 2011; 12(64):237-44. View

11.

Jansson M, Lund A . MicroRNA and cancer. Mol Oncol. 2012; 6(6):590-610. PMC: 5528350. DOI: 10.1016/j.molonc.2012.09.006. View

12.

Schaefer E, Chung R . Anti-hepatitis C virus drugs in development. Gastroenterology. 2012; 142(6):1340-1350.e1. DOI: 10.1053/j.gastro.2012.02.015. View

13.

Soulat D, Burckstummer T, Westermayer S, Goncalves A, Bauch A, Stefanovic A . The DEAD-box helicase DDX3X is a critical component of the TANK-binding kinase 1-dependent innate immune response. EMBO J. 2008; 27(15):2135-46. PMC: 2453059. DOI: 10.1038/emboj.2008.126. View

14.

Mourelatos Z, Dostie J, Paushkin S, Sharma A, Charroux B, Abel L . miRNPs: a novel class of ribonucleoproteins containing numerous microRNAs. Genes Dev. 2002; 16(6):720-8. PMC: 155365. DOI: 10.1101/gad.974702. View

15.

Fang J, Kubota S, Yang B, Zhou N, Zhang H, Godbout R . A DEAD box protein facilitates HIV-1 replication as a cellular co-factor of Rev. Virology. 2004; 330(2):471-80. DOI: 10.1016/j.virol.2004.09.039. View

16.

Huang H, Shiffman M, Cheung R, Layden T, Friedman S, Abar O . Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. Gastroenterology. 2006; 130(6):1679-87. DOI: 10.1053/j.gastro.2006.02.032. View

17.

Zeisel M, Lupberger J, Fofana I, Baumert T . Host-targeting agents for prevention and treatment of chronic hepatitis C - perspectives and challenges. J Hepatol. 2012; 58(2):375-84. DOI: 10.1016/j.jhep.2012.09.022. View

18.

Fuller-Pace F, Moore H . RNA helicases p68 and p72: multifunctional proteins with important implications for cancer development. Future Oncol. 2011; 7(2):239-51. DOI: 10.2217/fon.11.1. View

19.

Swain M, Lai M, Shiffman M, Cooksley W, Zeuzem S, Dieterich D . A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology. 2010; 139(5):1593-601. DOI: 10.1053/j.gastro.2010.07.009. View

20.

Scheller N, Mina L, Galao R, Chari A, Gimenez-Barcons M, Noueiry A . Translation and replication of hepatitis C virus genomic RNA depends on ancient cellular proteins that control mRNA fates. Proc Natl Acad Sci U S A. 2009; 106(32):13517-22. PMC: 2714764. DOI: 10.1073/pnas.0906413106. View